Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cochlear implants cases in Alabama: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 21% on average (16 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 61 | 45% |
| 2020 | 2 | 64 | 49% |
| 2021 | 2 | 72 | 54% |
Cochlear implantation, children and adults. Professional codes (what the surgeon bills): CPT 69930.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Alabama; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 30 | 3,072−2.6%/yr | −2.6%/yr | 7.11.4× | 85% | 3,520 in 2030+2.3%/yr |
| Ear tubes & middle ear surgery |
Cochlear implants in every state, and its device makers · Every procedure market in Alabama · Every state · Compare with Florida
| 2024 |
| 101 |
| 64% |
| 2025 est. | ≈ 90 | – |
| 2026 est. | ≈ 100 | – |
| 2022 | 3 | 64 | 58% |
| 2023 | 4 | 94 | 62% |
| 2024 | 4 | 101 | 64% |
| 2025 from claims | – | 89 73–105 | 65% |
| 2026 forecast | – | 95 76–121 | 66% |
| 2027 forecast | – | 103 77–137 | 67% |
| 2028 forecast | – | 111 80–155 | 68% |
| 2029 forecast | – | 119 83–173 | 68% |
| 2030 forecast | – | 129 86–193 | 69% |
In 2025, 32% hospital outpatient, 68% surgery center.
| +0.8%/yr |
| 0.1 |
| 13% |
| 310 in 2030+1.7%/yr |
| Tennessee | 7 | 196+7.3%/yr | +7.3%/yr | 0.3 | 28% | 270 in 2030+5.8%/yr |
| North Carolina | 5 | 190+11%/yr | +11%/yr | 0.2 | 21% | 290 in 2030+7.5%/yr |
| South Carolina | 6 | 138+5.8%/yr | +5.8%/yr | 0.2 | 17% | 310 in 2030+15%/yr |
| Maryland | 4 | 119+4%/yr | +4%/yr | 0.1 | 0% | 110 in 2030−0.9%/yr |
| Georgia | 4 | 116+11%/yr | +11%/yr | 0.1 | 0% | 220 in 2030+11%/yr |
| Virginia | 3 | 109+5.6%/yr | +5.6%/yr | 0.1 | 0% | 130 in 2030+3.6%/yr |
| 5 |
| 329−8.1%/yr |
| −8.1%/yr |
| 0.82.3× |
| 70% |
| 320 in 2030−0.5%/yr |
| Sleep apnea & airway implants | 3 | 147+137%/yr | +137%/yr | 0.31.4× | 0% | 130 in 2030−1.5%/yr |
Med-El leads with 46% of company spending on these surgeons in 2025, +12 pts on 2024.
In 2025, 6 companies reported engagement with Alabama’s surgeons worth $6,568 in consulting, speaking, meals and travel tied to these products, about $1,642 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 15 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.